§ 12-15-35-1 “Appropriate and medically necessary” defined
§ 12-15-35-2 “Board” defined
§ 12-15-35-3 “Compendia” defined
§ 12-15-35-4 “Counseling” defined
§ 12-15-35-4.5 “Covered outpatient drug” defined
§ 12-15-35-5 “Criteria” defined
§ 12-15-35-6 “Drug-disease contraindication” defined
§ 12-15-35-7 “Drug-drug interaction” defined
§ 12-15-35-8 “Drug utilization review” or “DUR” defined
§ 12-15-35-9 “Intervention” defined
§ 12-15-35-10 “Overutilization or underutilization” defined
§ 12-15-35-11 “Pharmacist” defined
§ 12-15-35-12 “Physician” defined
§ 12-15-35-13 “Prospective DUR” defined
§ 12-15-35-14 “Retrospective DUR” defined
§ 12-15-35-15 “Standards” defined
§ 12-15-35-16 “SURS” defined
§ 12-15-35-17 “Therapeutic appropriateness” defined
§ 12-15-35-17.5 “Therapeutic classification” or “therapeutic category” defined
§ 12-15-35-18 “Therapeutic duplication” defined
§ 12-15-35-18.5 Application of chapter
§ 12-15-35-18.7 Formulary requirements
§ 12-15-35-19 Drug utilization review board; establishment
§ 12-15-35-20 Membership of board
§ 12-15-35-20.1 Conflicts of interest
§ 12-15-35-20.5 Therapeutics committee established; members; limitations; terms; votes; meetings
§ 12-15-35-21 Board; appointment; term
§ 12-15-35-22 Qualifications of board members
§ 12-15-35-23 Physician appointments; geographic balance
§ 12-15-35-24 Reappointment of members
§ 12-15-35-25 Chairman; compensation; expenses
§ 12-15-35-26 Additional staff
§ 12-15-35-27 Retrospective and prospective DUR program responsibility
§ 12-15-35-28 Duties of the board; preferred drug list; report
§ 12-15-35-28.5 Therapeutics committee duties
§ 12-15-35-28.7 Submitting initial preferred drug list; limitations on restrictions; advance notice to providers; implementation; prior authorization limitation; rules
§ 12-15-35-29 Quorum; majority vote on DUR criteria and standards for prescribing
§ 12-15-35-30 Local practices; monitoring
§ 12-15-35-31 Intervention; approval; requisites
§ 12-15-35-32.1 Annual report contents
§ 12-15-35-34 Confidential identifying information; release of cumulative nonidentifying information
§ 12-15-35-35 Prior approval program for outpatient drugs; standards
§ 12-15-35-36 Advisory committees
§ 12-15-35-37 Medicaid state plan; inclusion of retrospective and prospective DUR program
§ 12-15-35-38 DUR program guidelines and procedures
§ 12-15-35-39 Retrospective DUR requisites
§ 12-15-35-40 Prospective DUR requisites
§ 12-15-35-41 Board activities under IC 34-30-15
§ 12-15-35-42 Meetings
§ 12-15-35-43 Confidentiality; pharmacist data and information
§ 12-15-35-43.5 Prohibiting the release of proprietary or confidential information obtained under certain circumstances
§ 12-15-35-44 Confidentiality; violations; penalty
§ 12-15-35-45 Outpatient drug formulary; requirements
§ 12-15-35-46 Review of proposed formulary
§ 12-15-35-47 Review of changes to formulary
§ 12-15-35-48 Board review of managed care organization prescription drug program
§ 12-15-35-49 Information provided by office
§ 12-15-35-50 Maximum allowable cost schedule for drugs; pharmacy participation in Medicaid program
§ 12-15-35-51 Advisory committee; duties; report

Terms Used In Indiana Code > Title 12 > Article 15 > Chapter 35 - Drug Utilization Review

  • Amendment: A proposal to alter the text of a pending bill or other measure by striking out some of it, by inserting new language, or both. Before an amendment becomes part of the measure, thelegislature must agree to it.
  • board: refers to the drug utilization review board created under this chapter. See Indiana Code 12-15-35-2
  • compendia: means those resources widely accepted by the medical profession in the efficacious use of drugs, including the following sources:

    Indiana Code 12-15-35-3

  • Contract: A legal written agreement that becomes binding when signed.
  • counseling: means the activities conducted by a pharmacist to inform Medicaid recipients about the proper use of drugs as required by the board under this chapter. See Indiana Code 12-15-35-4
  • covered outpatient drug: has the meaning set forth in 42 U. See Indiana Code 12-15-35-4.5
  • criteria: means the predetermined and explicitly accepted elements that are used to measure drug use on an ongoing basis to determine if the use is appropriate, medically necessary, and not likely to result in adverse medical outcomes. See Indiana Code 12-15-35-5
  • DUR: means the program designed to measure and assess on a retrospective and a prospective basis the proper use of outpatient drugs in the Medicaid program. See Indiana Code 12-15-35-8
  • Evidence: Information presented in testimony or in documents that is used to persuade the fact finder (judge or jury) to decide the case for one side or the other.
  • Executive session: A portion of the Senate's daily session in which it considers executive business.
  • Fraud: Intentional deception resulting in injury to another.
  • in writing: include printing, lithographing, or other mode of representing words and letters. See Indiana Code 1-1-4-5
  • intervention: means an action taken by the board with a prescriber or pharmacist to inform about or to influence prescribing or dispensing practices or utilization of drugs. See Indiana Code 12-15-35-9
  • Month: means a calendar month, unless otherwise expressed. See Indiana Code 1-1-4-5
  • Oversight: Committee review of the activities of a Federal agency or program.
  • pharmacist: means an individual who is licensed as a pharmacist in Indiana under IC 25-26. See Indiana Code 12-15-35-11
  • physician: means an individual who is licensed to practice medicine in Indiana under Indiana Code 12-15-35-12
  • prospective DUR: means the part of the drug utilization review program that:

    Indiana Code 12-15-35-13

  • Quorum: The number of legislators that must be present to do business.
  • Remainder: An interest in property that takes effect in the future at a specified time or after the occurrence of some event, such as the death of a life tenant.
  • retrospective DUR: means the part of the drug utilization review program that assesses or measures drug use based on an historical review of drug use data against predetermined and explicit criteria and standards that are developed on an ongoing basis with professional input. See Indiana Code 12-15-35-14
  • standards: means the acceptable range of deviation from the criteria that reflects local medical practice and that is tested on the Medicaid recipient database. See Indiana Code 12-15-35-15
  • SURS: refers to the surveillance utilization review system of the Medicaid program. See Indiana Code 12-15-35-16
  • Testimony: Evidence presented orally by witnesses during trials or before grand juries.
  • therapeutic category: means a group of pharmacologic agents primarily characterized by a significant similarity of the biochemical or physiological mechanism by which these agents result in the intended clinical outcome. See Indiana Code 12-15-35-17.5
  • Year: means a calendar year, unless otherwise expressed. See Indiana Code 1-1-4-5